Why the study?
TGFBIp functions as a mediator of experimental sepsis, leading to the hypothesis that aloin could reduce TGFBIp-mediated severe inflammatory responses.
Key points are not available for this paper at this time.
Population
HUVECs and mice
Comparison
Aloin treatment vs control
Design
In vitro and animal experimental study
Aloin attenuates experimental sepsis inflammation; hypothesis-generating for human therapy, should not yet change practice.
species. Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix protein and released by primary human umbilical vein endothelial cells (HUVECs) and functions as a mediator of experimental sepsis. We hypothesized that aloin could reduce TGFBIp-mediated severe inflammatory responses in HUVECs and mice. Aloin effectively inhibited lipopolysaccharide (LPS)-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. Aloin suppressed TGFBIp-induced sepsis lethality and pulmonary injury. Therefore, aloin is a potential therapeutic agent for various severe vascular inflammatory diseases, with inhibition of the TGFBIp signaling pathway as the mechanism of action. [Formula: see text].
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: